Reconciling Systolic Blood Pressure Intervention Trial With Eighth Joint National Commission

A Nuanced View of Optimal Hypertension Control in the Chronic Kidney Disease Population

Ekamol Tantisattamo; Anum Hamiduzzaman; Peter Sohn; Rebecca Ahdoot; Ramy M. Hanna


Curr Opin Nephrol Hypertens. 2022;31(1):57-62. 

In This Article

American College of Cardiology and the American Heart Association

In 2019, the American College of Cardiology (ACC) and the American Heart Association (AHA) presented an in-depth guide to hypertension control.[24] These guidelines discuss the idea of lifestyle changes for JNC-8 prehypertension patients (BP 120mmHg-129/<80 mmHg).[24] The idea of factoring in 10-year cardiovascular risk (CVD) into the decision to treat stage I hypertension (BP 130–139/80–89 mmHg). This unique position of assigning CVD risk to decide whether to treat BP if >10% risk is akin to similar schemes in deciding on statin antihyperlipidemia therapy.[25,26] JNC stage II hypertension is to be routinely treated with pharmacotherapy according to the ACC/AHA guidelines.[24] These guidelines are unique in using cardiac risk stratification in deciding on pharmacotherapy versus nonpharmacological lifestyle therapy.